Bicycle Therapeutics plc

Bicycle Therapeutics plcverified

BCYC

Price:

$22.71

Market Cap:

$1.57B

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a...[Read more]

Industry

Biotechnology

IPO Date

2019-05-23

Stock Exchange

NASDAQ

Ticker

BCYC

The Enterprise Value as of November 2024 (TTM) for Bicycle Therapeutics plc (BCYC) is 680.33M

According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 680.33M. This represents a change of -99.83% compared to the average of 390.34B of the last 4 quarters.

Bicycle Therapeutics plc (BCYC) Historical Enterprise Value (quarterly & annually)

How has BCYC Enterprise Value performed in the past?

The mean historical Enterprise Value of Bicycle Therapeutics plc over the last ten years is 313.08M. The current 680.33M Enterprise Value has changed 21.63% with respect to the historical average. Over the past ten years (40 quarters), BCYC's Enterprise Value was at its highest in in the September 2024 quarter at 1.56T. The Enterprise Value was at its lowest in in the December 2017 quarter at -63474748.00.

Quarterly (TTM)
Annual

Average

313.08M

Median

182.50M

Minimum

13.93M

Maximum

1.13B

Bicycle Therapeutics plc (BCYC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Bicycle Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.50%

Maximum Annual Enterprise Value = 1.13B

Minimum Annual Increase = -85.51%

Minimum Annual Enterprise Value = 13.93M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023162.04M-72.21%
2022583.13M-48.45%
20211.13B406.22%
2020223.45M1.50%
201913.93M-85.51%
201896.14M4.66%
201791.86M-54.74%

Bicycle Therapeutics plc (BCYC) Average Enterprise Value

How has BCYC Enterprise Value performed in the past?

The current Enterprise Value of Bicycle Therapeutics plc (BCYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

625.44M

5-year avg

422.74M

10-year avg

313.08M

Bicycle Therapeutics plc (BCYC) Enterprise Value vs. Peers

How is BCYC’s Enterprise Value compared to its peers?

Bicycle Therapeutics plc’s Enterprise Value is less than IDEAYA Biosciences, Inc. (2.23B), less than AnaptysBio, Inc. (961.84M), greater than MeiraGTx Holdings plc (437.28M), less than Keros Therapeutics, Inc. (1.86B), greater than Homology Medicines, Inc. (-103303255.00), greater than Tenaya Therapeutics, Inc. (110.48M), less than IGM Biosciences, Inc. (934.26M), greater than Monte Rosa Therapeutics, Inc. (481.73M), greater than Stoke Therapeutics, Inc. (489.33M), less than Merus N.V. (3.00B), greater than Inhibrx Biosciences, Inc. (4.03M), less than immatics biotechnologies GmbH (904.75M), greater than Seer, Inc. (111.86M), greater than ORIC Pharmaceuticals, Inc. (616.74M), greater than Anebulo Pharmaceuticals, Inc. (44.62M), less than Cullinan Oncology, Inc. (802.58M), greater than C4 Therapeutics, Inc. (396.43M), greater than Adagene Inc. (71.65M), greater than Acrivon Therapeutics, Inc. Common Stock (206.30M), greater than Mineralys Therapeutics, Inc. (600.97M),

Build a custom stock screener for Bicycle Therapeutics plc (BCYC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Bicycle Therapeutics plc (BCYC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Bicycle Therapeutics plc's Enterprise Value?

What is the highest Enterprise Value for Bicycle Therapeutics plc (BCYC)?

What is the 3-year average Enterprise Value for Bicycle Therapeutics plc (BCYC)?

What is the 5-year average Enterprise Value for Bicycle Therapeutics plc (BCYC)?

How does the current Enterprise Value for Bicycle Therapeutics plc (BCYC) compare to its historical average?